Eupatilin is developed by Seoul National University Boramae Hospital.

What development phase is Eupatilin in?

Eupatilin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Eupatilin

Seoul National University Boramae Hospital · FDA-approved active Small molecule Quality 2/100

Eupatilin, marketed by Seoul National University Boramae Hospital, is a drug with a key composition patent expiring in 2028. The primary strength of Eupatilin lies in its established market presence, leveraging the hospital's reputation and clinical expertise. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Eupatilin
Sponsor	Seoul National University Boramae Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eupatilin CI brief — competitive landscape report
Eupatilin updates RSS · CI watch RSS
Seoul National University Boramae Hospital portfolio CI